From Germany: Most ADCs use microtubule inhibitors or DNA-damaging agents as their payload. Heidelberg Pharma believes a greater diversity is needed and has a unique amanitin payload for its programs

59 minutes ago
1 min read

CEO Dongzhou Jeffery Liu describes the science behind amanitin (it is based on natural poisons, which occur in the death cap mushroom) and discusses Heidelberg Pharma's lead program, a BCMA antibody-drug conjugate, and earlier stage ones targeting CD37 and PSMA. Plus, partnerships with Takeda and Huadong Medicine.

Recent Posts

See All

From Germany: The Head of Research at BioMed X, which was founded in Heidelberg but now does science around the globe, highlights a few key research projects

CorTec Neuro's brain-computer interface is designed to both stimulate the brain of those recovering from stroke and do thought based computer control. A patient in Seattle used his mind to play Pong

From Germany: HepaRegeniX hits a kinase that was discovered at the University of Tübingen to regenerate healthy liver cells when inhibited. They already have phase 1b data in hand from the Mayo Clinic

From Germany: Most ADCs use microtubule inhibitors or DNA-damaging agents as their payload. Heidelberg Pharma believes a greater diversity is needed and has a unique amanitin payload for its programs

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight